. Author manuscript; available in PMC: 2011 Mar 30.

Published in final edited form as: J Alzheimers Dis. 2011 Jan 1;24(1):187–196. doi: 10.3233/JAD-2010-101698

Table 3.

Paired-sample statistical analysis of AD-related pathology of subsets generated by excluding cases indicating neuropathological diagnosis of AD (CERAD criteria) and further excluding gender/age mismatches

	Mumbai sample (n = 76) Mean (SEM)	New York sample (n = 76) Mean (SEM)	F	p
Brain weight	1045.95 g (14.67)	1221.38 g (17.27)	42.73	0.000
DP (grades)	1.42 (0.23)	0.77 (0.12)	6.50	0.013
NFT in Hippocampus (grade)	1.27 (0.20)	1.15 (0.19)	0.32	0.57, ns
NFT in Hippocampus (count/mm²)	4.18 (0.85)	3.86 (0.89)	0.20	0.65, ns
NFT in EC (grades)	1.25 (0.21)	1.42 (0.18)	0.07	0.79, ns
NFT in EC (count/mm²)	3.68 (0.78)	4.13 (0.73)	0.01	0.92, ns
SP in Neocortex (count/mm²)	0.35 (0.14)	0.38 (0.12)	0.01	0.90, ns
Braak stage for NFT	1.02 (0.15)	1.14 (0.12)	0.30	0.58, ns
SP, Age adjusted CERAD score	0.30 (0.10)	0.23 (0.07)	0.10	0.78, ns

Abbreviations: AD = Alzheimer's disease; DP = diffuse plaques; EC = entorhinal cortex; NFT=neurofibrillary tangles; SP = senile plaques; CERAD = consortium to establish a registry for Alzheimer's disease [22].